Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
If you ever wondered how Snow White could have been poisoned by eating an apple, you probably did not realize how much this tale of folklore was based on cruel reality. Science has finally caught up with the Brothers Grimm who wrote the fairy tale: a recent outbreak of listeriosis Continue reading At Last, The Fairy Tale Becomes Clear…
Sometimes an article pops up addressing a question we have been mulling over for quite some time. It so happened with a recent publication which shed new light on penem dosing for ICU patients[1]. Conducted at a single Belgian centre (sic!), a standard dose of meropenem (1 g IV q8h Continue reading Meropenem Dosing for VAP: High + Prolonged Beats Conventional Dosing
Despite all the concern about the emergence of CRE pathogens worldwide, it is quite difficult to obtain hard quantitative, prospectively collected incidence figures. A recent article by Robert [1] and colleagues provides useful data from France. Using a practical definition of carbapenem-non-susceptibility (ertapenem > 0.5, imipenem, meropenem > 2, doripenem > 1), Continue reading CRE Surveillance Data from France